AlphaStreet Newsdesk powered by AlphaStreet Intelligence
ProKidney Corp. (PROK) reported a wider loss for the primary quarter of 2026 because the clinical-stage biotechnology firm continues to advance its cell remedy applications for continual kidney illness. The corporate posted a loss per share of $0.14 for the quarter, in contrast with a $0.13 loss in the identical interval final 12 months, representing a 7.7% enhance within the per-share loss.
Web loss earlier than revenue tax for the quarter reached $42.6M as ProKidney maintained its analysis and growth actions. Income got here in at $226,000 for the three-month interval, down 1.7% from $230,000 within the year-ago quarter. The minimal income base displays the corporate’s standing as a clinical-stage enterprise targeted totally on growing remedies moderately than commercializing merchandise.
ProKidney had 301,953,977 shares of Class A and Class B frequent inventory excellent on the finish of the quarter. The corporate operates within the biotechnology sector, the place substantial losses throughout the growth part are frequent as corporations make investments closely in medical trials and regulatory processes earlier than reaching commercialization.
Wall Road analysts preserve a typically optimistic outlook on the inventory, with consensus scores displaying 5 purchase suggestions, 4 maintain scores, and 1 promote ranking. The corporate continues its deal with growing revolutionary mobile therapies focusing on continual kidney illness, a situation affecting tens of millions of sufferers and representing a big unmet medical want.
This content material is for informational functions solely and shouldn’t be thought-about funding recommendation. AlphaStreet Intelligence analyzes monetary knowledge utilizing AI to ship quick and correct market data. Human editors confirm content material.
